1-甲基-1H-苯并咪唑-5-甲醛 | 279226-70-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1-甲基-1H-苯并咪唑-5-甲醛
• 英文名称: 1-methyl-1H-benzo[d]imidazole-5-carbaldehyde
• 英文别名: 1-Methyl-1H-benzimidazole-5-carboxaldehyde；1-methylbenzimidazole-5-carbaldehyde
• CAS: 279226-70-9
• 化学式: C₉H₈N₂O
• mdl: MFCD09261052
• 分子量: 160.175
• InChiKey: PZIDCZRIHGNHPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Methyl-1h-benzimidazole-5-carboxaldehyde
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Methyl-1h-benzimidazole-5-carboxaldehyde
CAS number: 279226-70-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H8N2O
Molecular weight: 160.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基-1H-苯并咪唑-5-甲醛 在 哌啶 、 copper(l) iodide 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 53.0h， 生成 (Z)-3-((1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-((1-methyl-1H-benzo[d]imidazol-5-yl)methylene)thiazolidine-2,4-dione
  参考文献：
  名称：

  一些新型苯并咪唑-1,2,3-三唑-噻唑烷-2,4-二酮缀合物作为微管蛋白聚合抑制剂的设计与合成

  摘要：

   抽象的 目的：值得注意的是，苯并咪唑、2,4-二酮噻唑烷和1,2,3-三唑药效团在抗癌药物发现中发挥着重要作用。为了克服已报道的抗有丝分裂化合物的局限性，我们课题组首次将这三种药效团结合起来，并揭示了它们的体外抗癌和抗有丝分裂活性。方法：作为我们开发新型抗癌药物的一部分，在本研究中，我们集中于通过哌啶合成苯并咪唑-噻唑烷-2,4-二酮-1,2,3-三唑（ VIIa–VIIl ）催化 Knoevenagel 缩合和 Cu(I) 催化叠氮-炔环加成反应是关键方法。然后，通过IC 50值研究体外抗癌和微管蛋白聚合抑制( VIIa-VIIl )。最后，使用 AutoDock 工具研究了三种有效化合物 ( VIIg )、( VIIh ) 和 ( VIIk ) 与 α,β-微管蛋白的对接相互作用。结果与讨论：三种化合物（ VIIg ）、（ VIIh ）和（ VIIk ）对 A549、MCF-7 和 HeLa

  DOI：

  10.1134/s1068162024040307
• 作为产物：
  描述：

  1-甲基-1H-苯并咪唑-5-甲醇 在 二氧化锰 作用下， 以 丙酮 为溶剂， 反应 72.0h， 以to give 0.63 g of product的产率得到1-甲基-1H-苯并咪唑-5-甲醛
  参考文献：
  名称：

  Calcium receptor modulating agents

  摘要：

  本发明的化合物由以下一般结构或其药学上可接受的盐所代表，以及含有它们的组合物，其中变量在此定义，它们用于减少或抑制PTH分泌，包括减少或抑制PTH分泌的方法以及用于治疗或预防与骨疾病相关的疾病，例如骨质疏松症，或与PTH分泌过多相关的疾病，例如甲状旁腺功能亢进症。本发明还涉及制备这种化合物的过程以及在这些过程中有用的中间体。

  公开号：

  US07176322B2

文献信息

• METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION
  申请人：JACKSON Paul Francis

  公开号：US20120302573A1

  公开（公告）日：2012-11-29

  This invention relates to methods for preventing, treating or ameliorating an MMP9 and/or MMP13 mediated syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a compound listed in the examples section of this specification, or a form, composition or medicament thereof. Disorders treated and/or prevented include rheumatoid arthritis.

  这项发明涉及预防、治疗或改善由MMP9和/或MMP13介导的综合症、紊乱或疾病的方法，包括向需要的受试者施用本说明书示例部分列出的化合物的有效量，或其形式、组合或药物。治疗和/或预防的疾病包括类风湿关节炎。
• Aminopyrimidine Kinase Inhibitors
  申请人：Baldino Carmen M.

  公开号：US20120270892A1

  公开（公告）日：2012-10-25

  Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1γ), casein kinase 2 (CK2), Pim-1, Pim-2, Pim-3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1γ), casein kinase 2 (CK2), Pim-1, Pim-2, Pim-3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway.

  披露了化合物、含有这些化合物的药物组合物，以及这些化合物和组合物作为酪蛋白激酶1（例如CK1γ）、酪蛋白激酶2（CK2）、Pim-1、Pim-2、Pim-3、TGFβ途径、Wnt途径、JAK/STAT途径和/或mTOR途径的调节剂的使用。还披露了用于治疗或预防由于酪蛋白激酶1（例如CK1γ）、酪蛋白激酶2（CK2）、Pim-1、Pim-2、Pim-3、TGFβ途径、Wnt途径、JAK/STAT途径和/或mTOR途径的异常生理活动引起的一系列治疗指征的用途。
• Substituted hydantoins
  申请人：Goodnow, Alan Robert

  公开号：US20060063814A1

  公开（公告）日：2006-03-23

  The present invention relates to compounds of the formula which are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as, cancer, cognative and CNS disorders and inflammatory/autoimmune diseases.

  本发明涉及以下公式的化合物，这些化合物在治疗以MEK高活性为特征的疾病方面具有用途。因此，这些化合物在治疗癌症、认知和中枢神经系统疾病以及炎症/自身免疫疾病等疾病方面具有用途。
• Substitution at the indole 3 position yields highly potent indolecombretastatins against human tumor cells
  作者：Raquel Álvarez、Consuelo Gajate、Pilar Puebla、Faustino Mollinedo、Manuel Medarde、Rafael Peláez

  DOI：10.1016/j.ejmech.2018.08.078

  日期：2018.10

  (TPI) and cytotoxicity against human cancer cell lines but cyano, methoxycarbonyl, formyl, and hydroxyiminomethyl substitutions at the indole 3-position restores potent TPI and cytotoxicity against sensitive human cancer cell lines. These highly potent substituted derivatives displayed low nanomolar cytotoxicity against several human cancer cell lines due to tubulin inhibition, as shown by cell cycle analysis

  对康维他汀A-4的抗性是通过3-羟基-4-甲氧基苯基（B环）的酚羟基和醚基的代谢修饰介导的。用N取代康普他汀A-4的B环-甲基-5-吲哚基降低了微管蛋白聚合抑制（TPI）和对人癌细胞系的细胞毒性，但吲哚3位上的氰基，甲氧基羰基，甲酰基和羟基亚氨基甲基取代恢复了对敏感的人癌细胞系的强效TPI和细胞毒性。如细胞周期分析，共聚焦显微镜和微管蛋白聚合抑制活性研究所示，由于微管蛋白的抑制作用，这些高效取代衍生物对几种人类癌细胞系均表现出较低的纳摩尔细胞毒性，并通过caspase-3激活促进了细胞杀伤作用。分子模型研究表明在秋水仙碱位点的结合。取代的combrestastatins显示出比同分异构combretastatins高的效力，并且羟基亚氨基甲基（21）和氰基（23）组，TPI值在亚微摩尔范围内，而细胞毒性则在纳摩尔和亚纳摩尔范围内。剂量反应和时程研究表明，药物浓度低至1 nM（23）或10 nM（21）导致15
• [EN] SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRAZINE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
  申请人：ANDREWS STEVEN W

  公开号：WO2018136661A1

  公开（公告）日：2018-07-26

  Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

  本文提供了Formula I的化合物及其立体异构体和药学上可接受的盐或溶剂，其中A、B、D、E、X1、X2、X3和X4在规范中给出的含义，这些化合物是RET激酶的抑制剂，可用于治疗和预防可以用RET激酶抑制剂治疗的疾病，包括由RET激酶介导的疾病或紊乱。